Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler
01 Apr 2024
Phase 3
Abingworth will provide up to $150 million to help fund Teva Pharmaceuticals’ development of an asthma rescue inhaler, the companies said Monday morning.
The asset, known as ICS-SABA/TEV-’248, entered Phase 3 testing last fall and will have results in the second half of 2026, according to a Teva presentation from January.
The inhaler could work for adults and children, Teva has said. It combines the “two most widely used molecules,” which are fluticasone propionate and albuterol sulfate. The Israel-based pharma in January touted a $2.5 billion potential market.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.